Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
5(56%)
Results Posted
100%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
1
11%
Ph phase_2
4
44%
Ph phase_1
2
22%
Ph phase_4
2
22%

Phase Distribution

2

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Completed(1)
Terminated(2)

Detailed Status

Recruiting4
Terminated1
Withdrawn1
Active, not recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 24 (44.4%)
Phase 31 (11.1%)
Phase 42 (22.2%)

Trials by Status

recruiting444%
terminated111%
withdrawn111%
active_not_recruiting111%
completed111%
not_yet_recruiting111%

Recent Activity

5 active trials
Showing 5 of 9
not_yet_recruitingphase_2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

NCT07485010
active_not_recruitingphase_1

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis

NCT03919435
recruitingphase_2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

NCT07202091
recruitingphase_2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

NCT07202078
recruitingphase_2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

NCT07202052
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07485010Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not Yet Recruiting
NCT03919435Phase 1

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis

Active Not Recruiting
NCT07202091Phase 2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

Recruiting
NCT07202078Phase 2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Recruiting
NCT07202052Phase 2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Recruiting
NCT06982105Phase 4

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

Recruiting
NCT05418777Phase 1

Treatment of Pneumocystis in COPD (the TOPIC Study)

Terminated
NCT03235947Phase 4

Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients

Completed
NCT00752375Phase 3

Antibiotic Prophylaxis in Children With Pyelonephritis

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9